Headlines about Teleflex (NYSE:TFX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Teleflex earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical technology company an impact score of 47.0323761354607 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern’s scoring:
- Eaton Vance Management Sells 18,083 Shares of Teleflex Incorporated (TFX) (americanbankingnews.com)
- Martingale Asset Management L P Sells 55,725 Shares of Teleflex Incorporated (TFX) (americanbankingnews.com)
- Teleflex to Present at Barclays Global Healthcare Conference (finance.yahoo.com)
- Analysts Issue Forecasts for Teleflex Incorporated’s Q1 2018 Earnings (TFX) (americanbankingnews.com)
- Q1 2018 EPS Estimates for Teleflex Incorporated Reduced by Jefferies Group (TFX) (americanbankingnews.com)
Teleflex (TFX) traded down $2.54 during midday trading on Tuesday, hitting $253.72. 476,040 shares of the stock were exchanged, compared to its average volume of 309,942. Teleflex has a 1-year low of $191.00 and a 1-year high of $288.78. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.33 and a quick ratio of 1.51. The firm has a market capitalization of $11,499.73, a P/E ratio of 77.59, a PEG ratio of 1.89 and a beta of 1.15.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Friday, March 2nd will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.54%. The ex-dividend date is Thursday, March 1st. Teleflex’s payout ratio is 41.59%.
A number of equities analysts have recently weighed in on the stock. Deutsche Bank downgraded shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price target on the stock. in a research note on Tuesday, November 14th. Needham & Company LLC upped their price target on shares of Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Jefferies Group upped their price target on shares of Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Piper Jaffray Companies assumed coverage on shares of Teleflex in a research note on Friday, November 10th. They issued an “overweight” rating and a $295.00 price target on the stock. Finally, ValuEngine downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $281.56.
In other Teleflex news, Director George Babich, Jr. sold 2,500 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $283.11, for a total transaction of $707,775.00. Following the transaction, the director now directly owns 9,581 shares of the company’s stock, valued at $2,712,476.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total transaction of $49,792.00. Following the transaction, the director now directly owns 8,080 shares in the company, valued at $2,011,596.80. The disclosure for this sale can be found here. Insiders have sold 10,100 shares of company stock worth $2,671,994 over the last three months. Company insiders own 2.39% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.